Bangladesh DGDA Medical Device Registration Guide: Classification, Import Permits, and Local Representative Requirements

Why Bangladesh Is a Growing Medical Device Market

Bangladesh, with a population exceeding 170 million and a rapidly expanding healthcare sector, is one of the largest emerging medical device markets in South Asia. The country imports approximately 85% of its medical devices, creating significant opportunity for international manufacturers who navigate the registration process successfully.

The market is projected to reach $820 million by 2025, growing at a compound annual growth rate (CAGR) of approximately 13%, driven by rising healthcare spending, an aging population (5.2% aged 65 and above as of 2021), and increasing demand for modern diagnostic and therapeutic equipment.

Since the enactment of the Drug and Cosmetics Act 2023 on September 18, 2023, all medical devices—including software—must be registered with the Directorate General of Drug Administration (DGDA) before they can be imported, manufactured, or sold in Bangladesh. This guide covers the complete registration pathway, classification system, documentation requirements, and practical considerations for market entry.

Regulatory Framework Overview

Governing Legislation

Regulatory Authority

The Directorate General of Drug Administration (DGDA), operating under the Ministry of Health and Family Welfare, is the sole regulatory authority for medical devices, pharmaceuticals, IVDs, medicated cosmetics, and food supplements in Bangladesh. DGDA's responsibilities include:

• Registering medical devices and IVDs
• Issuing import permits (indent approvals)
• Granting clearance from indent approvals
• Approving Maximum Retail Price (MRP)
• Conducting pharmacovigilance monitoring
• Performing market surveillance to ensure product quality

Device Classification System

Bangladesh classifies medical devices into four risk-based categories closely aligned with the ASEAN Medical Device Directive (AMDD) classification framework:

Classification determines the level of documentation, testing, and evaluation required. Class B, C, and D devices are subject to obligatory registration. IVDs follow the same four-tier system but have some classification rules that differ from general medical devices.

Registration Process: Two-Step DGDA Approval

Overview

For Class B, C, and D medical devices, registration follows a mandatory two-step process. DGDA's review committee meets quarterly to evaluate applications.

Step 1: Primary Review (Recipe Approval)

The first step is a completeness review, sometimes called "Recipe Approval." DGDA evaluates whether the application contains all required technical and administrative documents.

Purpose: Confirm application completeness with all required documents submitted as PDF/Xerox copies

Duration: 3–4 months (aligned with quarterly DGDA committee meetings)

Government fee: Approximately US$60

Required documents for Step 1:

• Legal agreement (copy) between the manufacturer and the local agent/distributor
• Letter of Authorization from the manufacturer
• ISO 13485 Quality Management System certificate
• CE certificate or equivalent regulatory approval (PDF copy, online verifiable)
• Free Sale Certificate (FSC) from country of origin
• For Class C and D: Additional FSC from a reference country (EU, USA, Canada, Australia, or Japan)
• Product catalog with specifications
• Technical documentation and test reports
• Product samples (typically 2 units) or color catalog
• Completed Annexure-3 form (prescribed DGDA form, prepared by the local agent)
• For B, C, D devices: Simplified "Master Formula" documenting product composition, component specifications, and sources (a DGDA-specific requirement originating from pharmaceutical regulation)

Note on "Master Formula": This is a Bangladesh-specific requirement originating from DGDA's pharmaceutical heritage. For medical devices, DGDA requires a simplified version focused on product composition, component specifications, and their sources rather than a detailed manufacturing formula. Incomplete submissions at this stage will be rejected and must wait for the next quarterly DGDA meeting.

Outcome: If approved, DGDA issues a Recipe Approval letter. If documents are incomplete, the application is returned and must be resubmitted at the next quarterly meeting.

Step 2: Final Registration

After receiving Recipe Approval, the applicant submits the final registration package with original documents.

Purpose: Full review of all submitted documentation

Duration: 30–40 days after Step 1 completion (may extend to 2–3 months in practice)

Government fee: Approximately US$600

Required documents for Step 2:

• Original Free Sale Certificate (FSC) attested by the Bangladesh Embassy in the country of origin
• Original empty product box/label for review
• All original technical documents referenced in Step 1
• For Class C and D: Original FSC from a reference country, also Bangladesh Embassy attested
• Complete packaging materials showing manufacturer name and address, batch/lot number, specifications, manufacturing date, expiry date, and sterility status

Outcome: DGDA issues the "Registration Certificate – Medical Device/IVD Import"

Class A Simplified Process

Class A devices follow a simplified registration pathway:

• No government fees required
• Simpler documentation: agency agreement, FSC (Bangladesh Embassy attested), EU Declaration of Conformity (PDF copy), product catalog, product sample (for uncommon products only)
• Registration does not expire (no renewal needed)
• Processing time: approximately 1 month

Local Representative Requirements

Mandatory Local Representation

Foreign manufacturers cannot register medical devices directly with DGDA. A local Bangladeshi entity must:

1. Submit the registration application and hold the Marketing Authorization Certificate
2. Correspond with DGDA on behalf of the manufacturer
3. Assume legal responsibility for the device in Bangladesh
4. Maintain the registration and handle renewals

The local representative does not need to be the importer. Manufacturers can appoint an independent license holder (such as a regulatory consulting firm) and work with separate commercial distributors for importation. This structure is strongly recommended to prevent situations where a distributor "holds the license hostage."

Authorized Representative Agreement

The agreement between the manufacturer and local representative must include:

• Scope of products covered
• Duration and termination provisions
• Rights and obligations of both parties
• Provisions for transferring the registration to a new representative
• Responsibilities for pharmacovigilance reporting

Free Sale Certificate and Reference Country Requirements

The FSC is one of the most critical and often underestimated requirements for Bangladesh registration:

By Device Class

Embassy Attestation

All FSCs must be attested by the Bangladesh Embassy in the issuing country. In 2026 practice, DGDA has been strictly enforcing this requirement—any unattested copies will be rejected during Step 2 review. This process can add 2–4 weeks to preparation timelines and must be planned for in advance.

For manufacturers in countries without a Bangladesh Embassy, the FSC may need to be routed through a neighboring country's embassy, which can further extend timelines.

Quality System Requirements

Manufacturers who already hold QMS certification and product approval from a recognized National Regulatory Authority (such as FDA, EU Notified Body, TGA, or PMDA) outside Bangladesh must produce those documents, which DGDA uses as part of its evaluation.

Import Licensing and Distribution Workflow

After obtaining the Registration Certificate, the import process follows a structured five-step workflow:

Step 1: Indent Approval (Proforma Invoice Approval)

The importer submits a proforma invoice to DGDA for approval. DGDA holds one indent meeting per month, and approval typically takes 30 days.

Required documents: Registration certificate copy, proforma invoice (4 copies)

Step 2: Letter of Credit (LC) Opening

Once the indent is approved, the importer opens a Letter of Credit through a Bangladeshi bank. Timeline depends on the bank.

Step 3: Customs Clearance

When the shipment arrives at Bangladesh customs, the importer applies to DGDA for clearance. DGDA verifies the quantity against the approved indent.

Processing time: 2–3 working days

Step 4: Maximum Retail Price (MRP) Approval

All medical devices in Bangladesh must have an MRP affixed to their local labeling. The importer applies to DGDA for MRP certification.

Required documents: Registration certificate copy, approved proforma invoice, clearance copy, commercial invoice, bill of entry

Processing time: 30–40 days

Step 5: Ongoing Importation

For subsequent imports, the license holder issues a No Objection Certificate (NOC) for each importation, and the process repeats from Step 1.

Labeling Requirements

Medical device labeling in Bangladesh must comply with DGDA requirements:

• Language: English and Bengali bilingual labeling required
• Content: Must include manufacturer name and address, batch/lot number, specifications and size, manufacturing date, expiry date, and sterility status
• MRP: Maximum Retail Price must be displayed on the product label
• Packaging: Complete packaging materials must be submitted for DGDA review during registration
• Combined device packs: If devices are combined due to their intended purpose, the manufacturer must submit a declaration to DGDA confirming compatibility verification and that accompanying information is sufficient for safe use

Sample Import for Testing and Registration

Before registration, manufacturers often need to import a small number of units for testing purposes. This requires a No Objection Certificate (NOC) for Samples from DGDA, which allows customs clearance of a limited number of units solely for "Testing and Registration Purposes."

For Class D devices where the National Control Laboratory (NCL) may lack testing capacity, DGDA's Technical Committee may accept:

• A Method Validation Report
• ISO 17025-accredited laboratory reports from the manufacturer's own testing facilities
• In 2026 practice, DGDA has been increasingly requesting "Sample Analysis" via a local government-designated expert physician to verify clinical handling

Fees and Timelines Summary

Registration Fees

Registration Timelines

Practical Timeline Budget

Including document preparation, embassy attestation, and both DGDA review steps, plan for 12–24 months from project kickoff to first commercial sale for Class B–D devices.

SaMD and Digital Health Considerations

Under the Drug and Cosmetics Act 2023, software has been formally classified as a medical device. For Software as a Medical Device (SaMD) products:

• Software must be registered with DGDA following the same classification and registration pathway
• If the SaMD's server is located outside Bangladesh, DGDA may request data localization information or local server audit documentation
• Cloud-based AI-assisted diagnostic systems require specific technical documentation about data handling and storage

Post-Market Obligations

Once a device is registered and commercialized in Bangladesh:

• Pharmacovigilance: The local representative must report adverse events to DGDA
• Market surveillance: DGDA conducts periodic market visits to verify product quality
• Recall history: Manufacturers must provide recall history for the past 2 years (duly signed on company letterhead) during registration and renewal
• Renewal: Class B, C, and D registrations must be renewed every 5 years

South Asia Market Strategy

Bangladesh as Part of a Regional Approach

Bangladesh can be strategically combined with other South and Southeast Asian registrations:

Practical Tips for Success

1. Start with Embassy attestation early — The Bangladesh Embassy attestation process for FSCs is often the longest single preparation step and DGDA is strict about it
2. Use an independent license holder — Separate the registration holder from the commercial distributor to maintain control over your market authorization
3. Leverage existing approvals — Having FDA clearance, CE marking, or approval from Australia/Japan/Canada significantly strengthens the application, especially for Class C and D
4. Plan for the quarterly meeting cycle — Step 1 applications are reviewed at quarterly DGDA committee meetings; missing a deadline adds 3 months to your timeline
5. Prepare Bengali labeling in advance — Bilingual labeling is mandatory and must be ready for the Step 2 submission
6. Budget for MRP approval — Maximum Retail Price certification is required before any commercial import and adds 30–40 days per import cycle

Key Takeaways

• Bangladesh requires DGDA registration for all medical devices under the Drug and Cosmetics Act 2023
• Classification follows a four-tier system (A–D) aligned with ASEAN MDD
• Registration is a two-step process: Recipe Approval (3–4 months) followed by Final Registration (1–3 months)
• A local Bangladeshi representative is mandatory and holds the Marketing Authorization Certificate
• Free Sale Certificates must be Bangladesh Embassy attested—plan 2–4 weeks for this step alone
• Class C and D devices require FSCs from both the country of origin and a reference country
• Registration validity is 5 years for Class B/C/D; Class A certificates do not expire
• Budget 12–24 months from project start to first commercial sale